| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 生物制药报告分部(元) | 95,826,200.47 | - | 104,178,683.83 | - | 78,351,402.74 |
| 体外诊断试剂分部(元) | 1,638,014.43 | - | 1,934,682.27 | - | 2,718,511.27 |
| 医药技术服务报告分部(元) | 92,992,963.52 | - | 142,542,600.49 | - | 186,748,564.57 |
| 原料药及医药中间体(元) | 34,848,083.68 | - | 26,102,751.22 | - | 16,549,575.26 |
| 技术服务收入(元) | - | 242,539,109.37 | - | 411,166,272.17 | - |
| 注射用埃普奈明(元) | - | 102,946,964.82 | - | 26,368,276.45 | - |
| 注射用鼠神经生长因子(金路捷)(元) | - | - | - | 120,845,378.96 | - |
| 注射用鼠神经生长因子(元) | - | 115,522,984.82 | - | - | - |
| 其他(元) | 211,766.40 | 80,440,696.16 | 305,060.34 | 90,594,196.40 | 256,500.95 |
| 营业成本(元) | |||||
| 生物制药报告分部(元) | - | - | - | - | - |
| 体外诊断试剂分部(元) | - | - | - | - | - |
| 医药技术服务报告分部(元) | - | - | - | - | - |
| 原料药及医药中间体(元) | - | - | - | - | - |
| 技术服务收入(元) | - | 148,514,151.92 | - | 227,833,857.61 | - |
| 注射用埃普奈明(元) | - | 38,596,860.95 | - | - | - |
| 注射用鼠神经生长因子(金路捷)(元) | - | - | - | 24,189,365.79 | - |
| 注射用鼠神经生长因子(元) | - | 28,506,377.55 | - | - | - |
| 其他(元) | - | 94,951,770.14 | - | - | - |
| 毛利(元) | |||||
| 生物制药报告分部(元) | - | - | - | - | - |
| 体外诊断试剂分部(元) | - | - | - | - | - |
| 医药技术服务报告分部(元) | - | - | - | - | - |
| 原料药及医药中间体(元) | - | - | - | - | - |
| 技术服务收入(元) | - | 94,024,957.45 | - | 183,332,414.56 | - |
| 注射用埃普奈明(元) | - | 64,350,103.87 | - | - | - |
| 注射用鼠神经生长因子(金路捷)(元) | - | - | - | 96,656,013.17 | - |
| 注射用鼠神经生长因子(元) | - | 87,016,607.27 | - | - | - |
| 其他(元) | - | -14,511,073.98 | - | - | - |
| 毛利率(%) | |||||
| 生物制药报告分部(%) | - | - | - | - | - |
| 体外诊断试剂分部(%) | - | - | - | - | - |
| 医药技术服务报告分部(%) | - | - | - | - | - |
| 原料药及医药中间体(%) | - | - | - | - | - |
| 技术服务收入(%) | - | 38.77 | - | 44.59 | - |
| 注射用埃普奈明(%) | - | 62.51 | - | - | - |
| 注射用鼠神经生长因子(金路捷)(%) | - | - | - | 79.98 | - |
| 注射用鼠神经生长因子(%) | - | 75.32 | - | - | - |
| 其他(%) | - | -18.04 | - | - | - |
| 收入构成(%) | |||||
| 生物制药报告分部(%) | 42.49 | - | 37.87 | - | 27.53 |
| 体外诊断试剂分部(%) | 0.73 | - | 0.70 | - | 0.96 |
| 医药技术服务报告分部(%) | 41.24 | - | 51.82 | - | 65.61 |
| 原料药及医药中间体(%) | 15.45 | - | 9.49 | - | 5.81 |
| 技术服务收入(%) | - | 44.79 | - | 63.36 | - |
| 注射用埃普奈明(%) | - | 19.01 | - | 4.06 | - |
| 注射用鼠神经生长因子(金路捷)(%) | - | - | - | 18.62 | - |
| 注射用鼠神经生长因子(%) | - | 21.34 | - | - | - |
| 其他(%) | 0.09 | 14.86 | 0.11 | 13.96 | 0.09 |
| 毛利构成(%) | |||||
| 生物制药报告分部(%) | - | - | - | - | - |
| 体外诊断试剂分部(%) | - | - | - | - | - |
| 医药技术服务报告分部(%) | - | - | - | - | - |
| 原料药及医药中间体(%) | - | - | - | - | - |
| 技术服务收入(%) | - | 40.72 | - | 65.48 | - |
| 注射用埃普奈明(%) | - | 27.87 | - | 0.00 | - |
| 注射用鼠神经生长因子(金路捷)(%) | - | - | - | 34.52 | - |
| 注射用鼠神经生长因子(%) | - | 37.69 | - | - | - |
| 其他(%) | - | -6.29 | - | 0.00 | - |